Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) stock rose Friday with a session volume of 38.35 million compared to the average volume of 2.36 million, as per data from Benzinga Pro.
The gastrointestinal-focused biotechnology company released financial guidance for the full year 2026.
Ironwood expects 2026 Linzess US net sales of $1.125 billion-$1.175 billion, with total revenue expectation of $450 million-$475 million.
Also Read: Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
The company expects 2026 adjusted EBITDA of over $300 million.
Ironwood reaffirmed 2025 Linzess US sales guidance of $860 million-$890 million, revenue expectation of $290 million-$310 million, and adjusted